Biotechnology News 21 October 2025

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing

28 October 2025

Biotechnology·Investment News·Pharma Industry·Stock Market

Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Stock Skyrockets on Saudi Arabia Deal Announcement Co-Diagnostics’ stock price erupted on Monday after the company unveiled a strategic joint venture in the Middle East. Shares of the small-cap diagnostics firm opened around $0.59 and quickly soared, at one point up 133% to

27 October 2025

Biotechnology·Company News·Financial Analysis·Investing·Stock Market

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening

27 October 2025

Biotechnology·Pharmaceutical Industry·Stock Market

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Stock Price Rollercoaster in 2025 CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels Genengnews.

27 October 2025

Biotechnology·Investment Analysis·Stock Market

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the

27 October 2025

Biotechnology·Clinical Trials·Mergers & Acquisitions·Pharmaceutical Industry·Stock Market

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

AI-Driven “TechBio” Strategy Recursion’s narrative centers on its AI-enhanced drug discovery platform. Founded in 2013 in Salt Lake City, Recursion has spent years building RecursionOS, a giant database of cellular images and chemical data powered by machine learning Biotechhealthx. The

26 October 2025

Artificial Intelligence·Biotechnology·Investing·Stock Market

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

Recent FDA Approval and Market Reaction NeurAxis’s Oct. 24, 2025 announcement of FDA 510(k) clearance for its PENFS device immediately grabbed market attention. The clearance authorizes use in adults (8 years and up) for functional abdominal pain associated with FD

24 October 2025

Biotechnology·FDA Approvals·Investment News·Stock Market

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 Investing, after a volatile October run (ranging roughly $0.26–$0.84). The stock has surged ~28% on Oct 23 (to $0.5675 Financialcontent) after a prior drop (–23% on Oct 8 Benzinga). Recent

24 October 2025

Biotechnology·Clinical Trials·Pharmaceuticals·Stock Market

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform (originating from Naldini’s research) into its production pipeline Investing. “By making our clinically validated LVV plasmid DNA technology

24 October 2025

Biotechnology·Investment Analysis·Pharma News·Stock Market

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to

24 October 2025

Biotechnology·Cancer Research·Pharma Industry·Stock Market

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) Globenewswire. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) Globenewswire. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to

21 October 2025

Analyst Ratings·Biotechnology·Healthcare·Investment·Stock Market

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance Stockanalysis Stockanalysis Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) Stockanalysis. Trading volume is light (hundreds of thousands of shares),

21 October 2025

Biotechnology·Investing·Pharmaceuticals·Stock Market

Biotechnology News 21 October 2025 - 28 October 2025